Myth to test
Made to order means fully reviewed.
What holds up
As of September 2026, compounded medicines are not FDA-approved, even when a licensed pharmacy supplies them.
Ask what evidence supports this exact made-to-order medicine.
Orientation · Peptides, sorted
Same word. Different products.
A menu can put a familiar medicine next to a little-known ingredient. That does not make them equal. Ask what the actual product is.
What the product’s category tells you
FDA stands for Food and Drug Administration, the agency that reviews US medicines.
| What is offered | What it means, and what to ask |
|---|---|
| An approved product | Ozempic and Wegovy injections contain semaglutide. Both have FDA approval as of September 2026: Ozempic treats type 2 diabetes, while Wegovy is for losing weight and keeping it off. Mounjaro and Zepbound injections contain tirzepatide. The approved uses, as of September 2026, are type 2 diabetes for Mounjaro and losing weight and keeping it off for Zepbound. Approval is for a specific product and use, not everything with the same ingredient name. Ask: What condition is this product meant to treat? |
| A made-to-order medicine | For a compounded medicine, a doctor or pharmacist makes it to order instead of supplying an approved product already made. As of September 2026, compounding can meet a medical need that an approved medicine does not address. Ask: What need makes a made-to-order version relevant to me? |
| A research label | In guidance checked in September 2026, the FDA warns against weight-loss products labelled for research but intended for people. Their quality is unknown, and harm is possible. Ask: Why is something labelled for research being offered as treatment? |
Why an older shortage story is not enough
As of September 2026, neither semaglutide injections nor tirzepatide was on the FDA’s national shortage list.
A local pharmacy’s empty shelf does not put a medicine on the national shortage list.
Federal law restricts pharmacies and doctors from regularly copying medicines already sold ready-made, or making large amounts of those copies, as of September 2026.
An exception can apply when the person prescribing identifies a change to the medicine that makes an important difference for one named patient.
For example, a made-to-order medicine might leave out a dye you are allergic to.
Ask: What is changed in this medicine, and why does that change matter for my medical care?
A lower price alone is not that difference.
Ask for the product, not a nickname
BPC-157 names a peptide ingredient, not an approved treatment for an illness. As of September 2026, no medicine containing BPC-157 had US approval.
If someone mentions BPC-157, ask which health problem they mean and what evidence supports using it for that problem.
Researchers are studying retatrutide, an experimental medicine, for losing weight and keeping it off. As of September 2026, it had no US approval.
According to the FDA, federal law bars doctors and pharmacies from making medicines to order with retatrutide, as of September 2026.
Research results and a product offered for care are separate questions. Ask which exact medicine the health professional is discussing.
Read the FDA’s product guidanceNext: check a path to Seattle care